CCA
DTIL icon

Catalyst Capital Advisors’s Precision BioSciences DTIL Stock Holding History

Catalyst Capital Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12
Closed -$5K – 443
2019
Q2 		$5K Hold
12
– – ﹤0.01% 390
2019
Q1 		$6K Buy
+12
New +$6.37K ﹤0.01% 344

Other funds holding DTIL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Catalyst Capital Advisors's DTIL Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Precision BioSciences (DTIL) in Q3 2019, closing a stake of 12 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in DTIL in Q1 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 72 funds tracked by Wall St. Rank hold DTIL as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining Precision BioSciences position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 12 Precision BioSciences shares in Q3 2019, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in Precision BioSciences in Q1 2019 and held it in 2 quarters.
  • Catalyst Capital Advisors's Precision BioSciences position peaked at $6K in Q1 2019.
  • 72 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.